DPP4i+SGLT2i Combination Therapy for CAVD with first-in-class potential

DPP4i + SGLT2i
A potential First-in-class candidate to treat CAVD

DPP4i+SGLT2i Combination Therapy for CAVD with first-in-class potential

CAVD(Calcific Aortic Valve Disease), is a slow, progressive disorder that ranges from mild valve thickening, termed aortic sclerosis, to severe calcification with impaired leaflet motion and obstructed blood flow, termed aortic stenosis that usually develops from aging. In 2035, total CAVD diagnosed patient is predicted to about 4.9 million.

Symptoms: Dyspnea, Chest pain, Fainting, Heart failure

Current CAVD Treatments

  • Open-heart SAVR(Surgical Aortic Valve Replacement) procedure
  • Minimally invasive TAVR(Trans-catheter Aortic Valve Replacement) procedure

Limit of Current Treatments

  • Unmet Medical Needs: Despite the diagnosis, there are no prescribable drugs Valve replacement is the only and final treatment after long-term evaluation
  • High Risk: Open-heart procedure SAVR has a high operative mortality rate; On average, a replaced aortic valve lasts for 10 years.
  • High Price for Minimally Invasive Procedure: Total operation and treatment costs:US $110,000

MoA of this product:

  • DPP4i is a promising therapeutic target for CAVD.DPP4 cuts the IGF-1 that blocks the differentiation from VICs(Valvular interstitial cells) to osteoblast-like cells.
  • SGLT2i is well-known as a heart-protecting drug even if it was approved for diabetes. Recently Dapagliflozin and Empagliflozin showed a heart-protecting event in phase IV trials.
  • A combination of DPP4i and SGLT2i may have a more effective CAVD treatment by differentiated MoAs.

Competitor analysis: Currently there are limited competitors for CAVD projects

Advantages of product:

  • Dapagliflozin with Evogliptin showed synergistic effect
  • Based on the in vitro independent test of 4 kinds of Gliptins (Evogliptin, Linagliptin, Saxagliptin, Sitagliptin)and 4 kinds of Gliflozins (Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin), Evogliptin andDapagliflozin showed the best anti-calcification effect.
  • The company has filed a patent of DPP4i + SGLT2i combination for vascular or valvular stenosis which including CAVD and the PCT will be filed by this year soon, that means a strong protection of the combination therapy for CAVD treatment.

If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review.

Thank you very much!


打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2024年6月17日 18:28
下一篇 2024年6月18日 21:08